SCHEMBL8271978

SCHEMBL8271978

CN(C)Cc1ccc2c(c1)CN(Cc1ccc(Oc3ccccc3)cc1)C2=O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
MCHR1 Q99705 1/20 0.43
PRMT5 O14744 1/20 0.40
WDR77 Q9BQA1 1/20 0.40
ADAM17 P78536 1/20 0.39
HDAC1 Q13547 4/20 0.39
HDAC7 Q8WUI4 1/20 0.39
TNIK Q9UKE5 1/20 0.38
GRM5 P41594 1/20 0.38
CHRM5 P08912 1/20 0.38
EGLN1 Q9GZT9 1/20 0.38
ITGB3 P05106 1/20 0.37
ITGA2B P08514 1/20 0.37
APAF1 O14727 1/20 0.37
GAA P10253 1/20 0.37
CASP3 P42574 1/20 0.37
SENP8 Q96LD8 1/20 0.37
SENP7 Q9BQF6 1/20 0.37
SENP6 Q9GZR1 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2021547 0.87 MEN1 (0.41) MEN1KMT2AADAM17HDAC1HDAC7
SCHEMBL8272733 0.84 MCHR1 (0.41) MEN1KMT2AMCHR1EGLN1PARP1
SCHEMBL12641821 0.83 GRIN2B (0.47) MEN1KMT2APRMT5WDR77CHRM5
SCHEMBL2025564 0.82 MEN1 (0.44) MEN1KMT2APRMT5WDR77ADAM17
SCHEMBL2021878 0.82 GRM5 (0.47) MEN1KMT2AADAM17HDAC1HDAC7
SCHEMBL2028744 0.81 KMT2A (0.58) MEN1KMT2AHDAC1HDAC7EGLN1
SCHEMBL2024182 0.81 EGFR (0.48) MEN1KMT2A
SCHEMBL2026710 0.78 HDAC1 (0.47) MEN1KMT2AHDAC1HDAC7TNIK
SCHEMBL1002943 0.77 ADAM17 (0.57) MEN1KMT2APRMT5WDR77ADAM17
SCHEMBL2025909 0.76 TNIK (0.46) MEN1KMT2AMCHR1ADAM17HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2357169-A1 Isoindolone compounds and their use as metabotropic glutamate receptor potentiators AstraZeneca AB (SE) 2011-08-17 EP disclosed
US-7968570-B2 Isoindolone compounds and their use as metabotropic glutamate receptor potentiators ASTRAZENECA AB (SE) 2011-06-28 US disclosed
US-20090275578-A1 Isoindolone compounds and their use as metabotropic glutamate receptor potentiators ASTRAZENECA AB (SE) 2009-11-05 US disclosed
WO-2006020879-A1 ISOINDOLONE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS ASTRAZENECA AB (SE) 2006-02-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090275578-A1 Isoindolone compounds and their use as metabotropic glutamate receptor potentiators GRM1, GRIN1, GRM3 MEN1 2588/4885KMT2A 3975/4885MCHR1 258/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.